Pharmaceutical formulations of nitrite and uses thereof
AssigneeTheraVasc Inc.
InventorsChristopher KEVIL, Anthony GIORDANO, Douglas R. FLANAGAN, Panayiotis P. CONSTANTINIDES
Life of this patent
Estimating the term…
Abstract
The present invention relates to pharmaceutical compositions of nitrites such as inorganic nitrites, or any pharmaceutically acceptable salts, solvates, or prodrugs thereof, and the medical use of these compositions. The pharmaceutical compositions, which can be formulated for oral administration, can provide immediate release or extended release of the nitrite ion (NO2−). The pharmaceutical compositions of the invention are useful, for example, for the treatment of chronic tissue ischemia.
Claims18
A pharmaceutical composition comprising an effective amount of inorganic nitrite, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, and a pharmaceutically acceptable excipient, wherein administration of said pharmaceutical composition to a human results in a plasma concentration of nitrite ion that is maintained between 0.05 μM and 10 μM for up to 14 hours.
A pharmaceutical composition formulated for oral administration comprising an effective amount of inorganic nitrite, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, and a pharmaceutically acceptable excipient for delayed release of the inorganic nitrite, such that, when orally administered to a human subject, the inorganic nitrite is not substantially released in the stomach of said subject.
A pharmaceutical composition suitable for oral administration comprising
- (a) an effective amount of inorganic nitrite, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, and
- (b) an enteric coating layer,
- wherein said pharmaceutical composition is formulated such that, when administered to a human subject, the inorganic nitrite is not substantially released in the stomach of said subject and wherein administration of said pharmaceutical composition to a human results in a plasma concentration of nitrite ion that is maintained between 0.05 μM and 10 μM for up to 14 hours.
Dependencies are inferred from the claim text.